Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2017 / Cilt: 51 - Sayı: 3

Mucopolysaccharidosis Type 4 (Morquio Syndrome): A Case Report

Bir olgu nedeni ile mukopolisakkaridoz tip 4 (Morquio sendromu)

Pages
243–246
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is necessary to initiate enzyme replacement therapybefore the onset of gait disorders.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Mucopolysaccharidoses, develop with genetic transmission which cause destructive changes in various organs as a result of glycasoaminoglycans deposition in lysosomes.
📊
Key Findings & Data:Case: A 11-year-old male patient presented to our hospital with complaints of short stature, and bone deformities.
💡
Conclusion & Impact:It is necessary to initiate enzyme replacement therapybefore the onset of gait disorders.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Mucopolysaccharidoses, develop with genetic transmission which cause destructive changes in various organs as a result of glycasoaminoglycans deposition in lysosomes. Herein, we are presenting a case with Morquio syndrome so as to attract attention to this rarely seen disease. Case: A 11-year-old male patient presented to our hospital with complaints of short stature, and bone deformities. The parents were not relatives, and he had 3 healthy younger siblings. On physical examination, coarse facial features, hypertelorism, disproportionate short stature, genu valgum, pectus carinatum, kyphoscoliosis, were detected. He demonstrated a waddling gait. His neuromotor development was normal for his age. On bone radiograms, kyphoscoliosis, flared iliac wings, coxa valga, flattening of femoral epiphysis, widened ribs, and narrowed iliac wings were detected. Urine tests were positive for glycosaminoglycans (keratan sulphate). Enzymatic analysis revealed low levels of glucose-6-phosphatase [15 pmol/mg/hr, ], which made the final diagnosis.Conclusions: Morquio syndrome has Aand B types with similar clinical manifestations which are transmitted as an autosomal recessive trait. Tip 4A is a disease due to a deficiency of galactosamine6-sulfatase (GALNS) enzyme, which is encoded by the 16q24.3 gene, while Type 4B is characterized by deficiency of beta galactosidase. In both types of the disease, keratan sulphate, and chondrotin 6 sulphate accumulate. Also in our case manifestations became more prominent around age 1, and gradually progressed. Our patient without mental problems had typical skeletal signs on radiograms which is named dysostosis multiplex. It is necessary to initiate enzyme replacement therapybefore the onset of gait disorders.

Özet

Amaç: Mukopolisakkaridozlar, genetik geçişli ve lizozomlarda glikozamino glikan depolanması sonucu vücuttaki çeşitli organlarda hasara yol açan hastalıklardır. Burada nadir görülen bir tür olan Morquio sendromlu bu olguyu konuya dikkat çekmek amacı ile sunmaktayız.Olgu: Onbir yaşındaki erkek hasta, hastanemize boy kısalığı ve kemik bozuklukları nedeni ile başvurdu. Anne baba akraba değildi ve olgumuzun üç sağlıklı küçük kardeşi vardı. Fizik muayenede kaba yüz, hipertelorizm, orantısız boy kısalığı, çarpık bacak, pektus karinatum, kifoskolyoz saptandı. Ördekvari yürüyüşü vardı. Nöromotor gelişimi yaşına uygundu. Kemik grafilerinde kifoskolyoz, iliak kanatlarda parlama, koksa valga, femoral epifizlerde düzleşme, genişlemiş kaburga kemikleri ve dar iliak kanatlar tespit edildi. İdrarda glikozaminoglikan (keratan sülfat) pozitif bulundu. Enzimatik analizde glukoz-6fosfataz düşük bulunarak [15 pmol/mg/saat ] kesin tanı kondu.Sonuçlar: Morquio sendromunun benzer klinik tabloları olan ve otozomal resesif kalıtılan A ve B tipleri vardır. Tip 4A galactosamine-6-sulfatase (GALNS) enzim eksikliğine bağlı 16q24.3 geni ile kodlanan hastalık iken, Tip 4B beta galaktozidaz eksikliği ile ortaya çıkar. Her iki tip hastalıkta da, keratan sülfat ve kondrotin 6 sülfat birikmektedir. Bizim olgumuzda da bulgular 1 yaş civarında belirginleşmiş ve giderek ilerlemiştir. Zeka problemi olmayan hastamızın, dizostozis multipleks olarak adlandırılan kemik radyolojik bulguları tipiktir. Enzim replasman tedavisinin yürüme fonksiyonunu kaybetmeden başlanması önemlidir.

🔖

Cite This Article

ŞAHİN, K., ELEVLİ, M., KALKAN, T. (2017). Mucopolysaccharidosis Type 4 (Morquio Syndrome): A Case Report. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 51 - Sayı: 3, 243–246. https://ajindex.com/articles/363751

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Wenger DA, Coppola S, Liu SL. Insights into the diagnosis and treatment of lysosomal storage diseases. Arch Neurol 2003; 60: 322-8. [CrossRef] 2. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat 1995; 6: 288- 302. [CrossRef] 3. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis 1996; 19: 357-65. [CrossRef] 4. Mikles M, Stanton RP. A review of Morquio syndrome. Am J Orthop (Belle Mead NJ) 1997; 26: 533-40 5. Nelson J, Broadhead D, Mossman J. Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part I: Clinical and biochemical findings. Clin Genet 1988; 33: 111-20. [CrossRef] 6. Holzgreve W. Gröbe H, von Figura K, Kresse H, Beck H, Mattei JF. Morquio syndrome: clinical findings in 11 patients with MPS IVA and 2 patients with MPS IVB. Hum Genet 1981; 57: 360-5. [CrossRef] 7. Nelson J, Thomas PS. Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part III: Odontoid dysplasia. Clin Genet 1988; 33: 126-30. [CrossRef] 8. Wappner RS. Lysosomal storage disorders. In: McMillan JA, Feigin RD, DeAngelis C, Jones MD (eds). Oski's Pediatrics. Principles and Practice. 4th ed. Philadelphia:Lippincott, Williams Wilkins; 2006.p.2199-206. 9. TomatsuS, Montano AM, Nishioka T, Gutierrez MA, Pena OM, Tranda Firescu GG, et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IV A (Morquio A). Hum Mutat 2005; 26: 500-12. [CrossRef] 10. Simon AJ, Martin B, Rossella P, Ken M, Hui W, Ke Y, et al. Safety and clinical activity of elosul-fase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y. Pediatr Res 2015; 78: 717-22. [CrossRef]